BIOGNOSYS
14.12.2021 16:02:08 CET | Business Wire | Press release
Biognosys, a leading developer and provider of next-generation proteomics technology and solutions, and Thermo Fisher Scientific, the world leader in serving science with innovative technologies, purchasing convenience and pharmaceutical services, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.
The agreement leverages the two companies’ complementary capabilities in mass spectrometry-based proteomics. Biognosys deploys Thermo Fisher Scientific instruments in its state-of-the-art facility for contract research services, while Thermo Fisher Scientific co-markets Biognosys software and kits with its Thermo Scientific™ instruments and workflows.
Biognosys’ Biomarker Discovery services for pharmaceuticals and diagnostics development integrate Thermo Scientific Orbitrap™ and FAIMS Pro™ instruments with Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and Spectronaut™ Data Independent Acquisition (DIA) analysis software to offer unprecedented depth, quantitative precision, and throughput for unbiased discovery. This new and improved solution searches the complete proteome to quantify up to 3,000 of the most relevant proteins in biofluids and more than 10,000 proteins in tissue biopsies.
Andreas Huhmer, PhD, Senior Director Life Sciences Research OMICS Marketing at Thermo Fisher Scientific: “Biognosys’ Biomarker Discovery solutions maximize all innovative features of the Thermo Scientific Orbitrap mass spectrometers to analyze the proteome with industry-leading depth. Their unbiased discovery approach, coupled with their state-of-the-art data analysis capabilities, unlocks possibilities for transformative biomarker discovery.”
Through the companies’ extended co-marketing agreement , laboratories with in-house proteomics facilities have access to efficient, accurate, and scalable mass spectrometry-based proteomics workflows combining Thermo Scientific mass spectrometry instruments with Biognosys’ proteomics data analysis software and kits.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys: “Our agreement with Thermo Fisher Scientific has helped to greatly advance Biognosys’ mission to give researchers a look at every angle of the proteome to unlock discoveries and transform clinical research. Our suite of software and kits uniquely complements Thermo Scientific mass spectrometry instruments and workflows to enable researchers to obtain the best possible data and insights in any proteomics application.”
Biognosys’ leading DIA software solution, Spectronaut, is compatible with Thermo Scientific Orbitrap Exploris™ 480 and Thermo Scientific™ Q Exactive™ instruments.
Biognosys’ SpectroDive™ software for automated mass spectrometry method set-up, signal processing, and analysis of targeted proteomics experiments supports the SureQuant IS-PRM targeted acquisition workflow.
The PQ500™ Reference Peptide Kit from Biognosys can quantify more than 500 proteins in human plasma/serum samples as part of the SureQuant IS-PRM workflow with the Orbitrap Exploris™ 480 mass spectrometer, delivering sensitive and accurate quantitation to drive scientific progress or clinical decision making.
Learn more about the insights that can be uncovered through the Biognosys and Thermo Fisher Scientific partnership from Lukas Reiter’s presentation, “Recent Progress in Blood Proteomics” , during the Thermo Fisher Scientific dinner workshop at ASMS 2021.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QpiAI Open-Sources Its Quantum SDK to Accelerate Global Quantum Software Development8.7.2026 06:30:00 CEST | Press release
QpiAI, a globally leading full-stack quantum computing company, today released the QpiAI Quantum SDK as open-source software. Available now at https://github.com/qpiai/quantum-sdk, the QpiAI Quantum SDK gives developers, researchers, and startups an accessible, developer-friendly toolkit to build and run quantum algorithms and to connect their quantum development workflows directly to QpiAI's 8-qubit and 25-qubit quantum computers through QpiAI-QCloud (https://qcloud.qpiai.tech/). The release is designed to expand access to quantum software development for developers, researchers, universities, startups, and enterprise innovation teams worldwide. By open-sourcing the SDK, QpiAI is giving the global quantum community a practical foundation for building industry-specific quantum solutions across finance, logistics, materials, chemistry, security, AI, optimization, and advanced scientific computing. The QpiAI Quantum SDK provides a Python-based interface for circuit creation, simulation,
Access Advance Welcomes Wave of New Licensees to the HEVC Advance Patent Pool8.7.2026 02:00:00 CEST | Press release
Access Advance LLC, the leading HEVC patent pool administrator, today announced a significant expansion of the HEVC Advance Patent Pool, with 28 companies executing licenses in the first half of 2026. The new Licensees span consumer electronics, automotive, telecommunications, industrial technology, and professional security, reflecting the breadth of industries in which HEVC has become a foundational video technology. "HEVC remains the cornerstone of modern video delivery, and the demand we are seeing from new Licensees speaks to the long-term commercial relevance of this technology," said Peter Moller, CEO of Access Advance. "HEVC licensing activity has been consistently strong, and we are pleased to welcome a number of important new participants to the program." Notably, nine video surveillance equipment manufacturers have joined the HEVC Advance program as Licensees, ranging from three of the world's largest video surveillance equipment makers to specialized developers of security
Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 68.7.2026 00:22:00 CEST | Press release
Presented by NYU Langone Health and Powered by MerrellLottery Open Through July 20 The Empire State Building Observation Deck (ESB), atop the “World’s Most Famous Building,” today announced that general lottery registration is open for this year's Empire State Building Observation Deck Run-Up (ESBRU), which will run through July 20, 2026. The annual race, presented by NYU Langone Health and powered by Merrell, will take place on Oct. 6, 2026, at 8 p.m. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707902561/en/ Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 6 This year’s race marks the 48th anniversary of the event, in which 225 runners will race up 1,576 stairs of the iconic New York City landmark to reach the world-famous 86th Floor Observation Deck. “Every year, the Empire State Building Observation Deck Run-Up is a remarkable feat for all who participate as they race up to Tripadvi
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 20:36:00 CEST | Press release
A record-breaking sales value for a residential project in the UAEThe project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi1,700 residences sold within days after the launch15% non-UAE resident buyers81% new customers to Modon Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of laun
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom